Drug Trial Radar · NCT00345683
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Last checked: Nov 19, 2026Latest source record: Nov 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,021
Actual
Start
Jul 2007
Primary completion
Sep 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (care provider)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579). No new recruitment will take place during this booster phase of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Conditions
- Haemophilus Influenzae Type b
- Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)Biological
Booster dose by intramuscular injection
PedvaxHIBBiological
Booster dose by intramuscular injection
PrevnarBiological
Booster dose by intramuscular injection
M-M-R IIBiological
Single dose by subcutaneous injection
VarivaxBiological
Single dose by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Serious Adverse Events (SAEs)Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
- Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)Time frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
- Number of Subjects Reporting RashTime frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
- Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) VisitsTime frame: From fourth dose up to Day 30 after fourth dose vaccination (from study Month 10-13 up to study Month 11-14)
- Number of Subjects With Serious Adverse Events (SAEs)Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
- Number of Subjects With New Onset of Chronic Illnesses (NOCIs)Time frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
- Number of Subjects With RashTime frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
- Number of Subjects With Adverse Events Resulting in Emergency Room (ER) VisitsTime frame: From fourth dose through the end of the 6-month safety follow-up of the fourth dose phase (from study Month 10-13 up to study Month 16-19)
Locations
57 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Benton, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Madera, California
GSK Investigational Site
Slinas, California
GSK Investigational Site
West Covina, California
GSK Investigational Site
Boulder, Colorado
GSK Investigational Site
Longmont, Colorado
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Waukee, Iowa
GSK Investigational Site
West Desmoines, Iowa
GSK Investigational Site
Bardstown, Kentucky
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Bossier City, Louisiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Nies, Michigan
GSK Investigational Site
Portage, Michigan
GSK Investigational Site
Stevensville, Michigan
GSK Investigational Site
Saint Paul, Minnesota
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Ithaca, New York
GSK Investigational Site
New Hartford, New York
GSK Investigational Site
Syracuse, New York
GSK Investigational Site
Raleigh, North Carolina
GSK Investigational Site
Boardman, Ohio
GSK Investigational Site
Canton, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
North Canton, Ohio
GSK Investigational Site
South Euclid, Ohio
GSK Investigational Site
Erie, Pennsylvania
GSK Investigational Site
Greenville, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.